• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

青少年特发性关节炎、葡萄膜炎和多发性硬化症:两例病例描述及文献综述

Juvenile Idiopathic Arthritis, Uveitis and Multiple Sclerosis: Description of Two Patients and Literature Review.

作者信息

Chighizola Cecilia Beatrice, Ferrito Matteo, Marelli Luca, Pontikaki Irene, Nucci Paolo, Miserocchi Elisabetta, Caporali Roberto

机构信息

Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy.

Paediatric Rheumatology Unit, ASST G. Pini & CTO, 20122 Milan, Italy.

出版信息

Biomedicines. 2022 Aug 21;10(8):2041. doi: 10.3390/biomedicines10082041.

DOI:10.3390/biomedicines10082041
PMID:36009588
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9405697/
Abstract

Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood, while multiple sclerosis (MS) is a demyelinating disease of the central nervous system, characterized by remission and exacerbation phases. An association between MS and rheumatologic diseases, in particular rheumatoid arthritis, has been described and numerous studies acknowledge anti-TNF-α drugs as MS triggers. Conversely, the association between MS and JIA has been reported merely in five cases in the literature. We describe two cases of adult patients with longstanding JIA and JIA-associated uveitis, who developed MS. The first patient was on methotrexate and adalimumab when she developed dizziness and nausea. Characteristic MRI lesions and oligoclonal bands in cerebrospinal fluid led to MS diagnosis. Adalimumab was discontinued, and she was treated with three pulses of intravenous methylprednisolone. After a few months, rituximab was started. The second patient had been treated with anti-TNF-α and then switched to abatacept. She complained of unilateral arm and facial paraesthesias; brain MRI showed characteristic lesions, and MS was diagnosed. Three pulses of intravenous methylprednisolone were administered; neurological disease remained stable, and abatacept was reintroduced. Further studies are warranted to define if there is an association between JIA and MS, if MS represents JIA comorbidity or if anti-TNF-α underpins MS development.

摘要

幼年特发性关节炎(JIA)是儿童时期最常见的风湿性疾病,而多发性硬化症(MS)是一种中枢神经系统脱髓鞘疾病,其特征为缓解期和加重期。MS与风湿性疾病,特别是类风湿关节炎之间的关联已被描述,许多研究认为抗TNF-α药物是MS的诱发因素。相反,MS与JIA之间的关联在文献中仅报道过5例。我们描述了2例患有长期JIA及JIA相关葡萄膜炎的成年患者,他们后来患上了MS。首例患者在服用甲氨蝶呤和阿达木单抗时出现头晕和恶心。脑脊液中典型的MRI病变和寡克隆带导致了MS的诊断。停用阿达木单抗,她接受了3次静脉注射甲泼尼龙冲击治疗。几个月后,开始使用利妥昔单抗。第二例患者曾接受抗TNF-α治疗,然后改用阿巴西普。她主诉单侧手臂和面部感觉异常;脑部MRI显示典型病变,诊断为MS。给予3次静脉注射甲泼尼龙冲击治疗;神经系统疾病保持稳定,重新使用阿巴西普。有必要进行进一步研究以确定JIA与MS之间是否存在关联、MS是否代表JIA的合并症,或者抗TNF-α是否是MS发病的基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/768d/9405697/006d61e2d252/biomedicines-10-02041-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/768d/9405697/006d61e2d252/biomedicines-10-02041-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/768d/9405697/006d61e2d252/biomedicines-10-02041-g001.jpg

相似文献

1
Juvenile Idiopathic Arthritis, Uveitis and Multiple Sclerosis: Description of Two Patients and Literature Review.青少年特发性关节炎、葡萄膜炎和多发性硬化症:两例病例描述及文献综述
Biomedicines. 2022 Aug 21;10(8):2041. doi: 10.3390/biomedicines10082041.
2
Multiple Sclerosis in a Patient with Intermediate Uveitis and Juvenile Idiopathic Arthritis Treated with Adalimumab: A Case Report.阿达木单抗治疗中重度葡萄膜炎和幼年特发性关节炎患者的多发性硬化症:病例报告。
Ocul Immunol Inflamm. 2023 Nov;31(9):1873-1876. doi: 10.1080/09273948.2022.2113800. Epub 2022 Sep 23.
3
Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.阿达木单抗联合甲氨蝶呤治疗与幼年特发性关节炎相关的难治性葡萄膜炎:一项 RCT。
Health Technol Assess. 2019 Apr;23(15):1-140. doi: 10.3310/hta23150.
4
Concurrence of juvenile idiopathic arthritis and primary demyelinating disease in a young child.幼年特发性关节炎与小儿原发性脱髓鞘疾病的并发。
Mult Scler Relat Disord. 2019 Jan;27:20-22. doi: 10.1016/j.msard.2018.10.002. Epub 2018 Oct 3.
5
A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial).阿达木单抗联合甲氨蝶呤治疗青少年特发性关节炎相关性葡萄膜炎的临床疗效、安全性及成本效益的随机对照试验(SYCAMORE试验)
Trials. 2014 Jan 9;15:14. doi: 10.1186/1745-6215-15-14.
6
Comparable Efficacy of Abatacept Used as First-line or Second-line Biological Agent for Severe Juvenile Idiopathic Arthritis-related Uveitis.阿巴西普作为一线或二线生物制剂治疗重度青少年特发性关节炎相关葡萄膜炎的疗效相当。
J Rheumatol. 2016 Nov;43(11):2068-2073. doi: 10.3899/jrheum.151389. Epub 2016 Sep 15.
7
Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT).巴瑞替尼治疗幼年特发性关节炎相关葡萄膜炎或慢性前房抗核抗体阳性葡萄膜炎的有效性和安全性:一项开放标签、阿达木单抗活性对照的 3 期临床试验研究方案(JUVE-BRIGHT)。
Trials. 2021 Oct 9;22(1):689. doi: 10.1186/s13063-021-05651-5.
8
Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?儿童慢性风湿性疾病患者使用抗 TNF-α 药物治疗结核是否安全?
Rheumatol Int. 2012 Sep;32(9):2675-9. doi: 10.1007/s00296-011-2030-8. Epub 2011 Jul 26.
9
Ocular Involvement in Juvenile Idiopathic Arthritis: Classification and Treatment.青少年特发性关节炎的眼部受累:分类与治疗
Clin Rev Allergy Immunol. 2015 Dec;49(3):271-7. doi: 10.1007/s12016-014-8436-9.
10
Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.肿瘤坏死因子-α阻滞剂治疗二线药物难治性幼年特发性关节炎相关葡萄膜炎:一项多国调查结果
J Rheumatol. 2007 May;34(5):1146-50. Epub 2007 Mar 1.

引用本文的文献

1
A Rare Case of a Balo's Concentric Sclerosis-Like Lesion in a Young Adult Woman.一名年轻成年女性患巴洛同心性硬化样病变的罕见病例。
Cureus. 2023 Oct 10;15(10):e46803. doi: 10.7759/cureus.46803. eCollection 2023 Oct.

本文引用的文献

1
Variant rs4149584 (R92Q) of the TNFRSF1A gene in patients with familial multiple sclerosis.家族性多发性硬化症患者中TNFRSF1A基因的rs4149584(R92Q)变体
Neurologia (Engl Ed). 2025 Jan-Feb;40(1):10-21. doi: 10.1016/j.nrleng.2022.07.002. Epub 2022 Aug 10.
2
CSF TNF and osteopontin levels correlate with the response to dimethyl fumarate in early multiple sclerosis.脑脊液中肿瘤坏死因子和骨桥蛋白水平与早期多发性硬化症患者对富马酸二甲酯的反应相关。
Ther Adv Neurol Disord. 2022 Jun 21;15:17562864221092124. doi: 10.1177/17562864221092124. eCollection 2022.
3
Juvenile idiopathic arthritis.
幼年特发性关节炎
Nat Rev Dis Primers. 2022 Jan 27;8(1):5. doi: 10.1038/s41572-021-00332-8.
4
Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.纵向分析显示,多发性硬化症与 Epstein-Barr 病毒的高患病率相关。
Science. 2022 Jan 21;375(6578):296-301. doi: 10.1126/science.abj8222. Epub 2022 Jan 13.
5
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.风湿免疫领域的 Janus 激酶靶向治疗:一种基于机制的方法。
Nat Rev Rheumatol. 2022 Mar;18(3):133-145. doi: 10.1038/s41584-021-00726-8. Epub 2022 Jan 5.
6
Methotrexate related cutaneous adverse drug reactions: a systematic literature review.甲氨蝶呤相关皮肤不良反应:系统文献综述。
J Basic Clin Physiol Pharmacol. 2021 Oct 27;33(5):549-565. doi: 10.1515/jbcpp-2021-0165. eCollection 2022 Sep 1.
7
Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders.多发性硬化症合并自身免疫性疾病患者的治疗方法。
Ther Adv Neurol Disord. 2021 Aug 23;14:17562864211035542. doi: 10.1177/17562864211035542. eCollection 2021.
8
Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches.幼年特发性关节炎:从发病机制到治疗方法。
Pediatr Rheumatol Online J. 2021 Aug 23;19(1):135. doi: 10.1186/s12969-021-00629-8.
9
Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology.奥瑞珠单抗治疗多发性硬化症:安全性、有效性及药理学
Ther Clin Risk Manag. 2021 Jul 30;17:765-776. doi: 10.2147/TCRM.S282390. eCollection 2021.
10
Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?利妥昔单抗治疗多发性硬化症:我们是否已准备好监管批准?
Front Immunol. 2021 Jul 6;12:661882. doi: 10.3389/fimmu.2021.661882. eCollection 2021.